Calithera Biosciences Inc., a clinical-stage bio-pharmaceutical company based in South San Francisco, is dedicated to the development and discovery of small molecule compounds that target tumor metabolism and tumor immunology for cancer treatment in the United States. The company's pipeline includes the orally bioavailable arginase inhibitor INCB001158, which is in Phase 1/2 clinical trials for the treatment of hematology and oncology. Additionally, Calithera is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trials for the treatment of cystic fibrosis and chronic airway infection, and ATG-037, an orally bioavailable small molecule inhibitor of CD73, along with CB-668, an orally administered inhibitor of the enzyme IL4I1. Calithera also has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for human healthcare. The company collaborates with Pfizer to evaluate the efficacy of the PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib in combination with telaglenasta. Moreover, Calithera Biosciences has a collaboration and license agreement with Incyte Corporation for the development and commercialization of the small molecule arginase inhibitor INCB001158 and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences Inc. was founded in 2010.